ZINFORO® (Ceftaroline fosamil) achieved high clinical cure rates and showed evidence of rapid response in CAP
Overall, 70% of patients treated with ceftaroline fosamil achieved clinical stability and improvement in symptoms by Day 4.1,*,†
In the Phase III trials, overall clinical cure rates at the TOC visit were similar between ZINFORO® (ceftaroline fosamil) and ceftriaxone as given below2:
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
*ZINFORO® (ceftaroline fosamil) may be associated with an early clinical response, based on the clinical stability and symptom improvement criteria. An early clinical response does not predict the final clinical outcome for ZINFORO® (ceftaroline fosamil).3
†Data shown not to be statistically significant.3
CAP, community-acquired pneumonia; CE, clinically evaluable; CI, confidence interval; FOCUS, ceFtarOline Community-acquired pneUmonia trial versuS ceftriaxone in hospitalized patients; MITTE, modified intent-to-treat efficacy; q12h, every 12 hours; q24h, every 24 hours; TOC, test of cure.
References:
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.